Thymidine kinase (TK-1) in prognostic indicators for DLBCL

Incorporating TK-1 levels into prognostic indices for DLBCL improves risk stratification by enhancing the accuracy of patient grouping and potentially replacing LDH, addressing the limitations of current prognostic indicators.

JP7577647B2Active Publication Date: 2024-11-05F HOFFMANN LA ROCHE & CO AG
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021510976
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-08-31
Filing Date
2019-08-30
Publication Date
2024-11-05
Estimated Expiration
2039-08-30

AI Technical Summary

Technical Problem

Current prognostic indicators for diffuse large B-cell lymphoma (DLBCL) lack accuracy and reliability, necessitating the development of more precise biomarkers for risk stratification of patients.

Method used

Incorporating thymidine kinase 1 (TK-1) levels, along with extranodal disease status and Ann Arbor stage, into prognostic indices to improve patient stratification by replacing and enhancing existing indicators like LDH, using methods such as immunoassays to measure TK-1 levels and enzyme activity.

Benefits of technology

Enhances the accuracy of prognostic indices by providing improved risk stratification, allowing for better patient grouping based on TK-1 levels, which correlate well with disease outcome, potentially replacing LDH in existing indices.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577647000013
    Figure 0007577647000013
  • Figure 0007577647000014
    Figure 0007577647000014
  • Figure 0007577647000015
    Figure 0007577647000015
Patent Text Reader

Abstract

The present disclosure relates to the discovery that thymidine kinase 1 (TK-1) is a valuable biomarker in methods for determining prognostic indicators (PIs) for risk stratification of patients suffering from aggressive B-cell lymphoma, particularly diffuse large B-cell lymphoma (DLBCL), the use of TK-1 in such PIs, and PIs that include the marker TK-1.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the discovery that thymidine kinase 1 (TK-1) is a valuable biomarker in methods for determining prognostic indicators (PIs) for risk stratification of patients suffering from aggressive B-cell lymphomas, in particular diffuse large B-cell lymphoma (DLBCL), the use of TK-1 in such PIs, and PIs comprising the marker TK-1. [Background technology]

[0002] Stratification of DLBCL patients into different risk groups is usually based on the scoring of prognostic indices. Currently, there are several prognostic indices (PIs) used for such patient stratification (Wight et al. Blood Reviews, 2018). The NCCN guidelines include the following: IPI, age-adjusted IPI, stage-modified IPI, and NCCN-IPI. The ESMO guidelines recommend IPI and age-adjusted IPI.

[0003] The standard International Prognostic Index (IPI) [Ziepert M.et al.,Journal of Clinical Oncology:28 / 14(2010)2373] is widely used in clinics to predict the prognosis of DLBCL patients treated with R-CHOP (rituximab + CHOP chemotherapy).The National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) is also very common [Zhou et al.,Blood,123,6:(2014)837].

[0004] Although there are some differences regarding the parameters used to determine the different PIs used in the field of DLBCL, there is a generally accepted concept that Ann Arbor stage, extranodal disease status, and - as the only biomarker - lactate dehydrogenase (LDH) are key components of each of the PIs mentioned above.

[0005] With any prognostic index or score, improvement is highly desirable, because the more accurate and reliable the index / score is, the better the stratification of patients.

[0006] Therefore, our task for this disclosure was to investigate whether there are biomarkers that can be used to improve the stratification of DLBCL patients, for example by determining a prognostic index or prognostic score.

[0007] This problem is addressed in this disclosure by providing a specification, examples, and embodiments as defined in the claims.

[0008] The parameters, namely extranodal disease status, Ann Arbor stage, and thymidine kinase 1 levels, have been shown to be key for determining some prognostic indicators for DLBCL patients.

[0009] Surprisingly, it was also found that the biomarker thymidine kinase 1 is not only able to replace the marker LDH in the PIs investigated, but also in combination with other parameters used in the PIs, is able to lead to an improvement of such PIs, i.e. an improved stratification of patients. Summary of the Invention

[0010] In one embodiment, the present disclosure relates to a method of determining a prognostic index (PI) for a diffuse large B-cell lymphoma (DLBCL) patient, comprising: a) determining at least the following parameters: i) extranodal disease status, ii) Ann Arbor stage, and iii) thymidine kinase 1 level, wherein absence of extranodal disease is assigned a value of 0, presence of extranodal disease is assigned a value of 1, Ann Arbor stage I or II is assigned a value of 0, Ann Arbor stage III or IV is assigned a value of 1, and a thymidine kinase level below a cutoff is assigned a value of 0 and a thymidine kinase level above a cutoff is assigned a value of at least 1; and b) summing the values ​​for i), ii) and iii) in determining the PI.

[0011] Also disclosed herein is a prognostic index for DLBCL patients and the use of a value for the level of TK-1 in determining a prognostic index (PI) for DLBCL, including a value for the level of thymidine kinase 1. Certain aspects of the present invention are also illustrated by the accompanying drawings. [Brief description of the drawings]

[0012] [Figure 1] Graphical representation of immunoassay data. In the left part of the figure, box plots are given. The y-axis (logarithmic scale) shows the concentration in ng / ml. In the right part of the figure, the area under the curve (AUC) is shown. (Abbreviations: Ctr = control samples, DLBCL = samples from diffuse large B-cell lymphoma patients). [Diagram 2] Graphical representation of LIAISON® Thymidine Kinase (activity) assay data. The left part of Figure 2 contains two box plots with units per ml on the y-axis (log scale). The right part of the figure shows the area under the curve (AUC). (Abbreviations: Ctr = control samples, DLBCL = samples from diffuse large B-cell lymphoma patients). [Diagram 3]Comparison of Methods Doming regression fits are shown in FIG. 3 correlating the x-axis of the LIAISON® thymidine kinase (activity) assay data with the y-axis of the prototype immunoassay. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] Detailed Description In one embodiment, the present disclosure provides a method for determining a prognostic index (PI; also called risk score or PI score) for a diffuse large B-cell lymphoma (DLBCL) patient, comprising: a) At least the following parameters: i) extranodal disease status, ii) Ann Arbor stage, and iii) thymidine kinase 1 levels. determining The absence of extranodal disease was assigned a score of 0, the presence of extranodal disease was assigned a score of 1, Ann Arbor stage I or II is assigned a value of 0, Ann Arbor stage III or IV is assigned a value of 1, and determining a level of thymidine kinase below a cutoff as a value of 0 and a level of thymidine kinase above said cutoff as a value of at least 1; b) In determining the PI, add up the values ​​for i), ii), and iii) The present invention relates to a method comprising the steps of:

[0014] In this specification, many documents are cited, including patent applications and manufacturer's manuals. The disclosures of these documents are not considered relevant to the patentability of this invention, but are incorporated herein by reference in their entirety. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.

[0015] Human thymidine kinase 1 (abbreviation: TK-1, hTK-1, hTK1 or TK1), (ATP:thymidine 5'-phosphotransferase, EC 2.7.1.21), is an enzyme involved in DNA precursor synthesis. Human thymidine kinase 1 consists of 234 amino acids as shown in SEQ ID NO:1. In the human body, TK-1 exists in various forms, such as dimers, tetramers, and high molecular weight polymers. These forms appear to depend on the presence of certain molecules, e.g., the presence or absence of adenosine triphosphate (ATP), the concentration of the hTK-1 protein itself, the type of protein, i.e., native or recombinant TK1, and the site / location of the protein, i.e., in serum or cytoplasm.

[0016] The level of thymidine kinase 1 in the sample of interest can be determined by any suitable means. The determination is performed in vitro. In one embodiment, the level of thymidine kinase 1 is determined in vitro from the sample of interest.

[0017] In one embodiment, the level of TK-1 is the enzyme activity level. Serum TK-1 enzyme activity can be measured, for example, using radioactive substrate 1251-dUrd (PROLIFIGEN® TK-REA, DiaSorin Inc.) or non-radioactive substrate TK-1 activity assay (TK LIAISON® assay, DiaSorin Inc.). In one embodiment, the level of thymidine kinase 1 is the protein level of thymidine kinase 1.

[0018] The term "cut-off value" refers to a decision point, usually a value and / or a concentration. Values ​​below the cut-off value are grouped into a first group, and values ​​above the cut-off value are grouped into a second group. Sometimes more than one cut-off value point is used. In this case, values ​​below the first cut-off value are grouped into a first group, values ​​above the first cut-off value and below the second cut-off value are grouped into a second group, values ​​above the second cut-off value and below the second cut-off value, etc.

[0019] It was a very surprising discovery that the levels of thymidine kinase 1 in DLBCL patients far exceeded the levels of TK-1 measured in samples from healthy individuals. In one embodiment, the cut-off value is determined in a baseline sample of a newly diagnosed DLBCL patient and is in the range of the 25% percentile to the 35% percentile of a newly diagnosed DLBCL patient.

[0020] In one embodiment, the cut-off value is determined based on samples taken from healthy controls. In one embodiment, the thymidine kinase cut-off value level is 4 times the average TK-1 level as determined in healthy individuals.

[0021] It was discovered that it was possible to use a single cutoff point for TK-1 and construct two groups of patients: those with thymidine kinase 1 levels below the cutoff, and those with TK-1 levels above the cutoff.

[0022] In one embodiment, the present disclosure relates to a method for determining PI as defined above, wherein the thymidine kinase 1 cut-off level is set at 4 times the average TK-1 level as determined in healthy individuals, with any thymidine kinase 1 level below the cut-off being assigned a value of 0 and any TK-1 level above the cut-off being assigned a value of 1.

[0023] It has further been found that it may be advantageous to establish two groups of patients based on the level of TK-1: patients with low thymidine kinase 1 levels, i.e., TK-1 levels below a cut-off value, an intermediate group, i.e., patients with TK-1 levels above the cut-off value and below a value corresponding to 20 times the average value determined in healthy individuals, and patients with high thymidine kinase levels, i.e., TK-1 levels above 20 times the average value determined in healthy individuals.

[0024] In one embodiment, the disclosure relates to a method for determining PI as defined above, wherein the thymidine kinase 1 cut-off level is set at 4 times the average value of TK-1 levels as determined in healthy individuals, thymidine kinase 1 levels, i.e. levels of TK-1 below the cut-off value, are assigned a value of 0, intermediate thymidine kinase levels, i.e. levels of TK-1 above the cut-off value and below a value corresponding to 20 times the average value as determined in healthy individuals, are assigned a value of 1, and high thymidine kinase levels, i.e. levels of TK-1 above 20 times the average value as determined in healthy individuals, are assigned a value of 2.

[0025] It has been found that the TK-1 levels with respect to protein concentration determined using an immunoassay method that is not yet fully standardized, and the TK-1 enzyme activity levels determined using the commercially available enzyme activity assay from DiaSorin, show a very good correlation (see FIG. 3). It is therefore also possible to give a cut-off value for the enzyme activity (U / l).

[0026] In one embodiment, the present disclosure relates to a method for determining PI, comprising and wherein the protein level cut-off for TK-1 is equivalent to 18 U / l of TK-1 enzyme activity.

[0027] In one embodiment, the present disclosure relates to a method for determining PI, comprising a cut-off value for protein levels equivalent to 18 U / l, wherein a TK-1 level above 18 U / l and below 88 U / l is assigned a value of 1, and a TK-1 level above 88 U / l is assigned a value of 2.

[0028] It has been discovered that for any patient, especially for those recently diagnosed with DLBCL, TK-1 should be measured and compared to a predefined cut-off value. If the measurement for a newly diagnosed patient is above the predefined cut-off value (binary approach), the patient is considered to have a higher risk score and is more likely to experience an unfavorable disease outcome.

[0029] It is also possible to define more than two risk groups based on a set of ascending cutoff values, for example in a trichotomous approach using a 0 (risk) point in determining the PI for patients with low levels of TK-1, a 1 (risk) point in determining the PI for patients with intermediate levels of TK-1, and a 2 (risk) point in determining the PI for patients with high levels of TK-1. Patients will then be assigned to one of the risk groups based on their TK-1 measurements, and the higher the risk score, the more unfavorable the disease outcome.

[0030] Alternatively, the TK-1 measurement could be directly converted to a continuous risk score based on a predefined suitable conversion function (e.g., log2 transformation). In one embodiment of the method according to the present disclosure, the PI is determined based on the log2 transformed TK-1 measurement. In one embodiment of the method according to the present disclosure, the PI is determined based on the continuous risk score of the TK-1 measurement. Any of these stratified or transformed TK-1 values ​​can be added to any of the existing prognostic indicators (with or without replacement of LDH).

[0031] In one embodiment, the method for determining a prognostic index as disclosed herein, comprising the parameters extranodal disease status, Ann Arbor stage, and thymidine kinase 1 level, further comprises the parameter age, where if age is below the cut-off value, the value is 0 points, and if age is above the cut-off value, the value is 1 point in determining the PI.

[0032] In one embodiment, the method for determining a prognostic indicator as disclosed herein, namely comprising the parameters extranodal disease status, Ann Arbor stage, and thymidine kinase 1 level, further comprises a parameter ECOG performance status, where if the ECOG performance status is ≦1, the value is 0 points in determining PI, and if the ECOG performance status is ≧2, the value is 1 point.

[0033] At least four different but related prognostic indexes for DLBCL are currently available and used in clinical practice, the International Prognostic Index (IPI), the "age-adjusted IPI", the Revised Standard International Prognostic Index (R-IPI), and the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI).

[0034] A "prognostic index" (PI) (also called risk score or PI score) provides a numerical value. Such a numerical value of PI is generated, for example, by summing the values ​​determined for each individual parameter (component) of such PI. In one embodiment, the method of determining PI according to the present disclosure is implemented in a computer readable program. In one embodiment, the method of determining PI according to the present disclosure is implemented into an app. The prognostic index or PI score can be used, for example, to divide / stratify patients into groups. Such groups can be, for example, groups with different risks of disease progression. Usually, about three or four groups are constructed, respectively: low risk group, intermediate risk group, and high risk group, or low risk group, intermediate low risk group, intermediate high risk group, and high risk group.

[0035] The "original" International Prognostic Index (IPI) in the field of DLBCL was described in 1993 by Shipp MA and Harrington DP, "A predictive model for aggressive non-Hodgkin's lymphoma"; The international non-Hodgkin's Lymphoma prognostic factors project, N. Engl. J. Med. 1993; 329(14):987-94. This paper also describes an age-adjusted IPI that groups patients over 60 years of age from those under 60 years of age. The disclosure of this reference is expressly incorporated herein by reference.

[0036] The "original" International Prognostic Index (IPI) includes the parameters age (>60 years=1 point), ECOG performance status (≥2=1 point), Ann Arbor stage (III or IV=1 point), LDH (>ULN=1 point) and extranodal site (>1=1 point). The risk groups resulting from the IPI score are as follows: low risk (0–1 point), low-intermediate risk (2 points), high-intermediate risk (3 points) and high risk (4 or 5 points).

[0037] The minimal complexity version of the age-adjusted IPI is applied to patients over 60 years of age. It includes the parameters Ann Arbor stage (III or IV=1 point), LDH (greater than ULN=1 point) and extranodal site (greater than 1=1 point). Four risk groups are determined: low risk (0 points), low intermediate risk (1 point), high intermediate risk (2 points), and high risk (3 points).

[0038] The age-adjusted IPI, applicable to patients 60 years of age or younger, also includes the parameters Ann Arbor stage (III or IV=1 point), LDH (above ULN=1 point) and extranodal site (above 1=1 point), but uses a slightly different scoring system. The four risk groups herein are low risk (0-1 points), low-intermediate risk (1-2 points), high-intermediate risk (2-3 points), and high risk (4 points).

[0039] As discovered by the inventors for the present invention, TK-1 can be used as a substitute for LDH in both the IPI and the age-adjusted IPI.

[0040] The (Revised) International Prognostic Index (R-IPI) [Sehn, et al., 2007] is widely used in clinics to predict the outcome of DLBCL patients treated with R-CHOP (rituximab + CHOP chemotherapy). The R-IPI contains five components, which are summed into a final risk score (Table 1). [Table 1]

[0041] In one embodiment, the method disclosed in the present invention, comprising the parameters for determining PI, i.e., extranodal disease status, Ann Arbor stage, and thymidine kinase 1 level, further comprises the parameters of age and Ann Arbor stage, where if age is 60 or less, the value is 0 points in determining PI, if age is more than 60, the value is 1 point, if Ann Arbor stage is II or less, the value is 0 points in determining PI, and if Ann Arbor stage is III or IV, the value is 1 point. In one embodiment of this method, extranodal disease is disease in more than one extranodal site (including bone marrow), which, if met, results in a score of 1 in determining PI. In one embodiment, the present invention relates to an improved R-IPI comprising the above parameters (components) from Table 1, where the level of TK-1 is used instead of the level of LDH. In one embodiment of the improved R-IPI, the thymidine kinase 1 cut-off level is set at 4 times the average TK-1 level as determined in healthy individuals, with thymidine kinase 1 levels below the cut-off being scored 0 and any TK-1 level above the cut-off being scored 1. In one embodiment of the improved R-IPI, the thymidine kinase cut-off level is set at 4 times the average TK-1 level as determined in healthy individuals, with low thymidine kinase levels, i.e. levels of TK-1 below the cut-off being scored 0, intermediate thymidine kinase levels, i.e. levels of TK-1 above the cut-off and below a value corresponding to 20 times the average as determined in healthy individuals, being scored 1, and high thymidine kinase levels, i.e. levels of TK-1 above 20 times the average as determined in healthy individuals, being scored 2.

[0042] The "TK-1 IPI" (IPI using TK-1 instead of LDH) risk groups remain as published when using a single cut-off point for the level of TK-1 as previously described, i.e. low risk (0-1 points), low intermediate risk (2 points), high intermediate risk (3 points), and high risk (4 or 5 points). The prognostic power of the "TK-1 IPI" (IPI using TK-1 instead of LDH) can be further improved by triangulating the values ​​determined for the TK-1 level. The corresponding risk groups are low risk (0 points), low intermediate risk (1 point), high intermediate risk (2-3 points), and high risk (4-6 points).

[0043] The "TK-1 R-IPI" (R-IPI using TK-1 instead of LDH) risk groups remain as published when a single cut-off point for the level of TK-1 as previously described is used, i.e. low risk group ("very good", 0 points), intermediate risk ("good", 1-2 points), high risk ("poor", 3-5 points). The prognostic power of the "TK-1 R-IPI" (IPI using TK-1 instead of LDH) can be further improved by triangulating the values ​​determined for the TK-1 level. The corresponding risk groups are low risk group ("very good", 0 points), intermediate risk ("good", 1-3 points), high risk ("poor", 4-6 points).

[0044] The National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) is a derivative of the R-IPI and contains the following risk components (Table 2): [Table 2]

[0045] In one embodiment, the method disclosed in the present invention, comprising the parameters for determining PI, i.e., extranodal disease status, Ann Arbor stage, and thymidine kinase 1 level, further comprises the parameters of age and ECOG performance status, where if age is 40 or less, the value is 0 points in determining PI, if age is more than 40 and less than 60, the value is 1 point, if age is more than 60 and less than 75, the value is 2 points, if age is more than 75, the value is 3 points in determining PI, if ECOG performance status is 1 or less, the value is 0 points in determining PI, and if ECOG performance status is 2 or more, the value is 1 point. In one embodiment of this method, extranodal disease is disease in one or more sites selected from bone marrow, central nervous system, liver, gastrointestinal tract, and lung, and if this criterion is met, the score is 1. In one embodiment, the present invention relates to an improved NCCN-IPI comprising the above parameters (components) from Table 2, where the level of TK-1 is used instead of the level of LDH. In one embodiment of the improved NCCN-IPI, the cut-off level of thymidine kinase is set at 4 times the average TK-1 level as determined in healthy individuals, with low thymidine kinase levels, i.e., levels of TK-1 below the cut-off, receiving a score of 0, intermediate thymidine kinase levels, i.e., levels of TK-1 above the cut-off and below a value equivalent to 20 times the average as determined in healthy individuals, receiving a score of 1, and high thymidine kinase levels, i.e., levels of TK-1 greater than 20 times the average as determined in healthy individuals, receiving a score of 2.

[0046] The "TK-1 NCCN-IPI" (NCCN-IPI using TK-1 instead of LDH) risk groups remained as published, i.e., low risk (0–1 points), high-intermediate risk (2–3 points), high-intermediate risk (4–5 points), and high risk (≥6 points).

[0047] As is evident from Tables 1 and 2 and the above descriptions of the "older" IPIs, there is consensus that Ann Arbor stage and extranodal disease, and lactate dehydrogenase (LDH) as the only biomarker, are key elements of each of the above-mentioned PIs for DLBCL.

[0048] As seen for the IPI, age-adjusted IPI, R-IPI, and NCCN-IPI, lactate dehydrogenase (LDH) values ​​are typically determined using the upper limit of normal (ULN): LDH levels below the ULN will receive a score of 0, and LDH levels above the ULN will receive at least a score of 1.

[0049] Ann Arbor staging is performed as described at https: / / www.ncbi.nlm.nih.gov / pubmed / 5121694 and https: / / www.ncbi.nlm.nih.gov / pubmed / 2809679, the disclosures of which are hereby incorporated by reference in their entireties.

[0050] ECOG (Eastern Cooperative Oncology Group) performance status (= "ECOG status") is determined as defined and described by Oken MM, Creech RH, Tormey DC, et.al., Eastern Cooperative Oncology Group, Robert Comis MD, Group Chair. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55.

[0051] All DLBCL PIs mentioned above use the same cut-off value for ECOG status (ECOG performance status), i.e., an ECOG status of 2 or more will score 1 point in the determination of each of these indicators, whereas an ECOD status of 0 or 1 will score 0 point. The same applies to ECOG status as part of the methods or prognostic indicators disclosed herein.

[0052] There is a broad consensus that "extranodal disease" refers to one further core element of any of the above-mentioned PIs. There are slight differences regarding the definition of extranodal disease between the various IPIs described in more detail above. As is clear from the given examples, the value of the level of TK-1 can be used and can be combined with any of the above-mentioned PIs. Therefore, in one embodiment, the present invention relates to a method for determining PI or PI itself, and the definition of extranodal disease is selected from disease in more than one extranodal site (including bone marrow) or disease in bone marrow, central nervous system, liver, gastrointestinal tract, lung (one or more).

[0053] The terms "sample" or "sample of interest" or "test sample" are used interchangeably herein. The sample is an in vitro sample, which will be analyzed in vitro and will not be returned to the body. In one embodiment, the sample of interest is taken from a patient who has been newly diagnosed with DLBCL and before treatment is started. Examples of samples include, but are not limited to, fluid samples such as blood, serum, plasma, synovial fluid, urine, saliva, and lymphatic fluid, or solid samples such as tissue extracts, cartilage, bone, synovium, and connective tissue. In one embodiment, the sample is selected from blood, serum, plasma, synovial fluid, and urine. In one embodiment, the sample is selected from blood, serum, and plasma. In one embodiment, the sample is serum or plasma.

[0054] The term "reference sample" as used herein refers to a sample that is analyzed in substantially the same manner as the sample of interest, and its information is compared with the information of the sample of interest.Therefore, the reference sample provides a standard that allows the information obtained from the sample of interest to be evaluated.The reference sample can be derived from a healthy or normal tissue, organ, or individual, thereby providing a standard for the health status of the tissue, organ, or individual.In one embodiment, the reference sample for determining the average value of TK-1 is derived from a healthy individual.

[0055] As further indicated above, the level of thymidine kinase used to determine the prognostic indicator is in one embodiment a protein level. A variety of methods for determining protein levels are available and within the skill of the art.

[0056] In one embodiment, the protein level of thymidine kinase is determined in immunoassay.Any kind of immunoassay can be used to measure the TK-1 protein level in sample.The example of immunoassay that can be used to measure the TK-1 level for later use in determining PI is enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), radioimmunoassay (RIA), or immunoassay based on luminescence, chemiluminescence, electrochemiluminescence or fluorescence.

[0057] One commercially available immunoassay is the Arocell hTK-1 assay, which is based on a microtiter plate format.

[0058] In one embodiment, the TK-1 levels used to determine the prognostic indicator are measured in a sandwich assay.

[0059] In a typical sandwich-type method, a primary antibody bound to or capable of being bound to a solid phase, and a detectably labeled secondary antibody each bind to the analyte with a different non-overlapping epitope. The first analyte-specific binding agent (e.g., an antibody) is either covalently or passively bound to a solid surface. The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride, or polypropylene. The solid support may be a tube, a bead, a microplate disk, or other surface suitable for carrying out an immunoassay. The binding process is well known in the art and generally consists of cross-linking covalent binding, or physical adsorption, and the polymer-antibody complex is washed in preparation for the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a sufficient time (e.g., 2-40 minutes or, more conveniently, overnight) and under appropriate conditions (e.g., room temperature to 40°C, such as 25°C to 37°C) to allow binding between the primary or capture antibody and the corresponding antigen. Following the incubation period, the solid phase containing and bound to the primary or capture antibody can be washed and incubated with a secondary or labeled antibody that binds to a different epitope on the antigen. The second antibody is conjugated to a reporter molecule that is used to indicate binding of the second antibody to the complex of the first antibody and the antigen of interest.

[0060] A very versatile alternative sandwich assay method involves the use of a solid phase coated with a first partner of a binding pair, e.g., a microparticle coated with paramagnetic streptavidin. Such microparticles are mixed and incubated with an analyte-specific binding agent bound to a second partner of the binding pair (e.g., a biotinylated antibody), a sample suspected of or containing an analyte whose second partner of the binding pair binds to the analyte-specific binding agent, and a second analyte-specific binding agent detectably labeled, e.g., with an electrochemiluminescent label as used herein. As will be clear to those skilled in the art, these components are incubated under appropriate conditions for a time sufficient to allow the labeled antibody to bind to the solid phase microparticles via the analyte, the second partner of the binding pair, and the analyte-specific binding agent (bound to) the first partner of the binding pair. Optionally, such an assay can include one or more washing steps(s).

[0061] As will be apparent to one of skill in the art, the sample can be contacted with the primary and secondary antibodies in any desired order, i.e., primary antibody first, secondary antibody, secondary antibody before the primary antibody, or simultaneously, for a time and under conditions sufficient to form a primary anti-hTK-1 antibody / hTK-1 / secondary anti-hTK-1 antibody complex.

[0062] As one skilled in the art will readily recognize, it is always a matter of routine experimentation to establish the time and conditions that are appropriate or sufficient for the formation of a complex between a specific anti-hTK-1 antibody and the hTK-1 antigen / analyte (anti-hTK-1 antibody / hTK-1 complex), or for the formation of a secondary or sandwich complex comprising hTK-1 (analyte) and a second anti-hTK-1 antibody complex (=first anti-hTK-1 antibody / hTK-1 / second anti-hTK-1 antibody complex).

[0063] Detection of the anti-hTK-1 antibody / hTK-1 complex can be carried out by any suitable means, the person skilled in the art is fully familiar with such means / methods.

[0064] In immunoassay methods for measuring levels of hTK-1, at least one antibody to hTK-1 usually contains a detectable label.

[0065] The term detectably labeled includes labels that can be detected either directly or indirectly.

[0066] Directly detectable labels provide detectable signals, or the labels interact with a second label to modify the detectable signals provided by the first or second labels, for example, by FRET (fluorescence resonance energy transfer). Labels such as fluorescent dyes and luminescent (including chemiluminescent and electrochemiluminescent) dyes (Briggs et al "Synthesis of Functionalised Fluorescent Dyes and Their Coupling to Amines and Amino Acids," J.Chem.Soc., Perkin-Trans.1 (1997) 1051-1058) provide detectable signals and are generally applicable to labeling methods. In one embodiment, detectably labeled refers to a label that provides or can be induced to provide a detectable signal, i.e., a fluorescent label, a luminescent label (e.g., a chemiluminescent label or an electrochemiluminescent label), a radioactive label or a metal chelate-based label, respectively.

[0067] A large number of labels (also referred to as dyes) are available which can be broadly grouped into the following categories, all of which collectively and each of which is an embodiment according to the present disclosure.

[0068] (a) Fluorescent dye Fluorescent dyes are described, for example, by Briggs et al. "Synthesis of Functionalized Fluorescent Dyes and Their Coupling to Amines and Amino Acids," J. Chem. Soc., Perkin-Trans. 1 (1997) 1051-1058).

[0069] Fluorescent labels or fluorophores include rare earth chelates (europium chelates), fluorescein-type labels (including FITC, 5-carboxyfluorescein, 6-carboxyfluorescein), rhodamine-type labels (including TAMRA), dansyl, lissamine, cyanine, phycoerythrin, Texas Red, and analogs thereof. Fluorescent labels can be attached to aldehyde groups contained within target molecules using the techniques disclosed herein. Fluorescent dyes and fluorescent labeling reagents include those commercially available from Invitrogen / Molecular Probes (Eugene, Oregon, USA) and Pierce Biotechnology, Inc. (Rockford, Ill.).

[0070] (b) Luminescent dye Luminescent dyes or labels can be further sub-classified into chemiluminescent dyes and electrochemiluminescent dyes.

[0071] Different classes of chemiluminescent labels include systems based on luminol, acridinium compounds, coelenterazine and analogues, dioxetanes, peroxyoxalic acid and peroxyoxalic acid derivatives. For immunodiagnostic procedures, mainly acridinium-based labels are used (a detailed overview is given in Dodeigne C. et al., Talanta 51 (2000) 415-439).

[0072] The main relevant labels used as electrochemiluminescent labels are electrochemiluminescent complexes based on ruthenium and iridium, respectively. Electrochemiluminescence (ECL) has proven to be very useful in analytical applications as a highly sensitive and selective method. ECL combines the analytical advantages of chemiluminescence analysis (absence of background light signal) with the ease of reaction control by applying an electrode potential. Generally, ruthenium complexes are used as ECL labels, especially [Ru(Bpy3]2+ (emitting photons at about 620 nm) regenerated with TPA (tripropylamine) in the liquid phase or at the liquid-solid interface.

[0073] Electrochemiluminescence (ECL) assays provide sensitive and accurate measurements of the presence and concentration of analytes of interest. Such techniques use a label or other reactant that can be induced to emit light when electrochemically oxidized or reduced in the appropriate chemical environment. Such electrochemiluminescence is generated by a voltage applied to the working electrode in a specific manner at a specific time. The light produced by the label is measured and indicates the presence or amount of the analyte. For a more complete description of such ECL techniques, see U.S. Pat. No. 5,221,605; U.S. Pat. No. 5,591,581; U.S. Pat. No. 5,597,910; PCT Publication No. WO 90 / 05296; PCT Publication No. WO 92 / 14139; PCT Publication No. WO 90 / 05301; PCT Publication No. WO 96 / 24690; PCT Publication No. US 95 / 03190; PCT Publication No. US 97 / 16942; PCT Publication No. US 96 / 24693; and PCT Publication No. US 97 / 24696. No. 06763, PCT Publication No. WO95 / 08644, PCT Publication No. WO96 / 06946, PCT Publication No. WO96 / 33411, PCT Publication No. WO87 / 06706, PCT Publication No. WO96 / 39534, PCT Publication No. WO96 / 41175, PCT Publication No. WO96 / 40978, PCT / US97 / 03653 and U.S. Patent Application No. 08 / 437,348 (U.S. Patent No. 5,679,519). Also, reference is made to the 1994 review of analytical applications of ECL by Knight, et al. (Analyst, 1994, 119:879-890) and the references cited therein. In one embodiment, the method according to the present invention is carried out using electrochemiluminescent labels.

[0074] Recently, iridium-based ECL labels have also been described (WO2012107419(A1)).

[0075] In one embodiment, the directly detectable label is a chemiluminescent or electrochemiluminescent label. The light produced by the label is measured and directly or indirectly indicates the presence or amount of the analyte.

[0076] The radiolabel employs a radioactive isotope (radionuclide), such as 3H, 11C, 14C, 18F, 32P, 35S, 64Cu, 68Gn, 86Y, 89Zr, 99TC, 111In, 123I, 124I, 125I, 131I, 133Xe, 177Lu, 211At, or 131Bi.

[0077] (d) Metal chelate complexes suitable as labels for imaging and therapeutic purposes are well known in the art (U.S. Patent Application No. 2010 / 0111856; U.S. Pat. No. 5,342,606; U.S. Pat. No. 5,428,155; U.S. Pat. No. 5,316,757; U.S. Pat. No. 5,480,990; U.S. Pat. No. 5,462,725; U.S. Pat. No. 5,428,139; U.S. Pat. No. 5,385,893; U.S. Pat. No. 5,739,294; U.S. Pat. No. 5,750,660; U.S. Pat. No. 5,834,456; Hnatowich et al, J. Immunol. Methods 65 (1983) 147-157; Meares et al, Anal. Biochem. 142 (1984) 68-78; Mirzadeh et al, Bioconjugate Chem.1(1990)59-65, Meares et al, J.Cancer(1990),Suppl.10:21-26, Izard et al,Bioconjugate Chem.3(1992)346-350, Nikula et al,Nucl.Med.Biol.22(1995)387-90, Camera et al. al,Nucl.Med.Biol.20(1993)955-62, Kukis et al,J.Nucl.Med.39(1998)2105-2110, Verel et al.,J.Nucl.Med.44(2003)1663-1670, Camera et al. al, J. Nucl. Med. 21 (1994) 640-646, Ruegg et al, Cancer Res.50(1990)4221-4226, Verel et al,J.Nucl.Med.44(2003)1663-1670, Lee et al,Cancer Res.61(2001)4474-4482, Mitchell,et al,J.Nucl.Med.44(2003)1105-1112, Kobayashi et al Bioconjugate Chem.10(1999)103-111, Miederer et al,J.Nucl.Med.45(2004)129-137, DeNardo et al,Clinical Cancer Research 4(1998)2483-90, Blend et al,Cancer Biotherapy&Radiopharmaceuticals 18(2003)355-363, Nikula et al J.Nucl.Med.40(1999)166-76, Kobayashi et al. al, J. Nucl. Med. 39 (1998) 829-36, Mardirossian et al, Nucl. Med. Biol. 20 (1993) 65-74, Roselli et al, Cancer Biotherapy & Radiopharmaceuticals, 14 (1999) 209-20). .

[0078] The immunoassay used in the Examples section employs several newly developed antibodies that are not yet publicly available and are therefore described in some detail below. All antibodies used bind specifically to human thymidine kinase 1 (hTK-1) of SEQ ID NO:1.

[0079] The term "specifically binds" (also referred to herein as "specifically interacts") means, in accordance with the present invention, that an antibody specifically binds only hTK-1, but does not cross-react or does not essentially cross-react with different proteins, particularly different proteins of similar structure, such as, for example, thymidine kinase 2 (SEQ ID NO:5).

[0080] Corresponding methods for analyzing the specificity of antibodies are described, for example, in Harlow & Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, and Harlow & Lane (1999) Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press. Non-limiting examples of suitable studies are, for example, binding studies, blocking and competition studies with structurally and / or functionally closely related molecules. These studies can be carried out, for example, by methods such as FACS analysis, flow cytometry titration analysis (FACS titration), surface plasmon resonance (SPR, for example, by BIAcore®), isothermal titration calorimetry (ITC), fluorescence titration, or by radioactively labeled ligand binding assay. Further methods include, for example, Western blot, ELISA (including competitive ELISA) test, RIA test, ECL test, and IRMA test.

[0081] In the context of the present invention, the term "antibody" relates to complete immunoglobulin molecules as well as to antigen-binding fragments thereof, such as Fab, Fab', F(ab')2, Fv, etc. Furthermore, the term relates to modified and / or altered antibody molecules as well as recombinantly or synthetically produced / synthesized antibodies. The term "antibody" also includes bifunctional antibodies, trifunctional antibodies, fully human antibodies, chimeric antibodies, and antibody constructs such as single chain Fv (scFv) or antibody fusion proteins.

[0082] As used herein, a "Fab fragment" refers to a fragment that contains one light chain and one heavy chain C. H 1 and variable regions. The heavy chain of a Fab molecule cannot form disulfide bonds with another heavy chain molecule. "Fab' fragments" are composed of the V H Domain and C H 1 domain, as well as C H 1 Domain and C HThe "F(ab')2 fragment" contains one light chain and a portion of one heavy chain, which also contains the region between the two domains, thereby allowing the formation of an interchain disulfide bond between the two heavy chains of the two Fab' fragments to form an F(ab')2 molecule. H 1 Domain and C H It contains two light chains and two heavy chains that contain a portion of the constant region between the two domains, which results in the formation of an interchain disulfide bond between the two heavy chains. Thus, the F(ab')2 fragment is composed of two Fab' fragments linked by disulfide bonds between the two heavy chains.

[0083] The Fab / c fragment contains both Fc and Fab determinants, the "Fc" region being the C region of the antibody. H 2 and C H The two heavy chain fragments contain two or more disulfide bonds and a C H The three domains are held together by hydrophobic interactions.

[0084] An "Fv region" comprises the variable regions from both the heavy and light chains, but lacks the constant regions. A "single-chain Fv" (also abbreviated as "scFv") is, in the context of the present invention, the V region of an antibody. H Domain and V L An scFv polypeptide is an antibody fragment having V domains, and these domains are present in a single polypeptide chain. Generally, the scFv polypeptide has a V domain that enables the scFv to form the desired structure for antigen binding. H Domain and V L It further comprises a polypeptide linker between the domains. Techniques described for the production of single chain antibodies are described, for example, in Pluckthun in The Pharmacology of Monoclonal Antibodies, edited by Rosenburg and Moore, Springer-Verlag, NY 113 (1994), 269-315.

[0085] The term "chimeric antibody" refers to an antibody that contains variable regions of a human or non-human species fused or chimerized to antibody regions (e.g., constant regions) from another species, either human or non-human (e.g., mouse, horse, rabbit, dog, cow, chicken).

[0086] As noted above, the term "antibody" also encompasses antibody constructs, such as antibody fusion proteins, in which an antibody contains, in addition to the domains defined herein by a specific amino acid sequence, additional domain(s) for the isolation and / or preparation of recombinantly produced constructs.

[0087] The antibody can be engineered to contain the CDRs disclosed and defined in the present invention while being a recombinant antibody, such as a recombinant rabbit antibody, or a heterohybrid antibody.

[0088] The term "recombinant antibody" includes all antibodies prepared, expressed, created, or isolated by recombinant means. Recombinant antibodies are, for example, antibodies obtained by B-cell PCR, or antibodies isolated from animals (e.g., mice) that are transgenic for human immunoglobulin genes, antibodies expressed using recombinant expression vectors transfected into host cells, antibodies isolated from recombinant combinatorial human antibody libraries, or antibodies prepared, expressed, created, or isolated by any other means including splicing human immunoglobulin gene sequences to other DNA sequences. Recombinant rabbit antibodies produced by B-cell PCR have variable and constant regions (if present) derived from rabbit germline immunoglobulin sequences. That is, the direct result of B-cell PCR is a binding-related fragment of an antibody, and the skilled artisan has no problem with, for example, what is construed as a full-length antibody, a chimeric antibody, or whatever "antibody" is desired / required.

[0089] One monoclonal antibody, MAB 6C6, has proven to be a very attractive tool for measuring TK-1 at the protein level via immunoassay. MAB 6C6 is characterized by a heavy chain variable domain of SEQ ID NO: 3 and a light chain variable domain of SEQ ID NO: 4. As described above, in one embodiment, the antibody or antigen-binding fragment thereof employed in the immunoassay for measuring TK-1 levels, as shown, for example, in the Examples section, binds to the same epitope as an antibody comprising a variable heavy chain (vHC) of SEQ ID NO: 3 and a variable light chain (vLC) of SEQ ID NO: 4.

[0090] Any monoclonal antibody or antigen-binding fragment thereof that binds to the same epitope as an antibody comprising a variable heavy chain (vHC) of SEQ ID NO: 3 and a variable light chain (vLC) of SEQ ID NO: 4 can be employed in an immunoassay for the measurement of TK-1. Such antibodies, and any antibodies having the same binding characteristics, can be, for example, variants of a given particular antibody, and can include, for example, amino acid substitutions, or can have a different vHC or a different vLC, or both.

[0091] The term "substitution" according to the present invention refers to the replacement of an amino acid with another amino acid. Thus, the total number of amino acids remains the same. The deletion of an amino acid at a particular position and the introduction of one (or more) amino acids at a different position are not explicitly encompassed by the term "substitution". Substitutions according to the present invention may be conservative amino acid substitutions or non-conservative amino acid substitutions. The term "conservative amino acid substitution" is well known in the art and refers to the replacement of an amino acid with a different amino acid having similar structural and / or chemical properties. Such similarity includes, for example, similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues involved. If an amino acid in one of the following groups is replaced by another amino acid of the same group, it is a conservative amino acid substitution. Nonpolar (hydrophobic) amino acids include alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

[0092] The "binding affinity" of an antibody measures the strength of the interaction between an epitope on a target antigen and the binding site of the antibody according to the formula: KD=kd / ka During the ceremony, KD=dissociation equilibrium constant [M] kd=dissociation rate constant [s -1 ] ka = association rate constant [M -1 ·s -1 ]

[0093] Further relevant parameters for the binding affinity of an antibody are: t / 2 = dissociation complex half-life = ln2 / kd / 60 [min] Rmax = maximum response value of the analyte [RU] MR: Molar ratio = maximum response ratio (Rmax) of the analyte

[0094] In one embodiment, the monoclonal antibody against hTK-1 used for immunological detection of TK-1 levels to determine PI binds to hTK-1 with at / 2 dissociation constant of 10 minutes or longer at 37°C.

[0095] An antibody that binds to the same epitope on hTK-1 is an antibody that competes with an antibody having a heavy chain variable domain of SEQ ID NO:3 and a light chain variable domain of SEQ ID NO:4 for binding to hTK-1.

[0096] Such competing antibodies can be identified based on their ability to compete in a standard hTK-1 binding assay with monoclonal rabbit antibody MAB 6C6, an antibody comprising a heavy chain variable domain of SEQ ID NO: 3 and a light chain variable domain of SEQ ID NO: 4. For example, BIAcore analysis, ELISA assays or flow cytometry can be used to demonstrate competition with a monoclonal antibody or binding fragment thereof having a heavy chain variable domain of SEQ ID NO: 3 and a light chain variable domain of SEQ ID NO: 4.

[0097] The ability of the test antibody to inhibit the binding of monoclonal rabbit antibody MAB 6C6 to human TK-1 demonstrates that the antibody can compete with monoclonal rabbit antibody MAB 6C6 for binding to the same epitope on hTK-1 as monoclonal rabbit antibody MAB 6C6, and therefore binds to that epitope.

[0098] As described, several different competition assays can be used to identify antibodies that compete with rabbit monoclonal antibody MAB 6C6 for its binding fragment having the heavy chain variable domain of SEQ ID NO:3 and the light chain variable domain of SEQ ID NO:4.

[0099] In an exemplary competitive assay, immobilized hTK-1 is incubated in a solution containing a first labeled antibody that binds to hTK-1 (e.g., an anti-hTK-1 monoclonal antibody or a binding fragment thereof having a heavy chain variable domain of SEQ ID NO: 3 and a light chain variable domain of SEQ ID NO: 4) and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to hTK-1. The second antibody may be present in a hybridoma supernatant. As a control, immobilized hTK-1 is incubated in a solution containing the first labeled antibody but not the second unlabeled antibody. After incubation under conditions that allow binding of the first antibody to hTK-1, excess unbound antibody is removed and the amount of label associated with immobilized hTK-1 is measured. If the amount of label associated with immobilized hTK-1 is substantially reduced in the test sample compared to the control sample, it indicates that the second antibody competes with the first antibody for binding to hTK-1. See, e.g., Harlow et al. Antibodies: A Laboratory Manual. Ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988).

[0100] The binding properties of an antibody, such as an anti-hTK-1 antibody, are best determined through real-time biosensor-based molecular interaction measurements, such as surface plasmon resonance spectroscopy, for which Biacore technology has become synonymous. In the Biacore system, antibodies can also be analyzed for competitive binding to the same epitope (i.e., for binding to the same epitope or overlapping epitopes). Experimental details are given in Example 3. In one embodiment, the competitive experiments to characterize antibodies for binding to the conformation-dependent epitopes identified herein are carried out on a BIAcore machine, as described in the Examples section.

[0101] In the prior art, serum or plasma samples are usually pretreated to produce a tetrameric and highly enzymatically active form of hTK-1. Sample pretreatment and measurement of hTK-1 from such pretreated samples is a very attractive method, which can achieve, for example, a very good correlation with hTK-1 enzyme activity.

[0102] The selection of a suitable pretreatment reagent is entirely within the capabilities of the skilled artisan. Such a pretreatment reagent would contain at least a reducing agent to convert oligomeric hTK-1 to tetrameric hTK-1. As explained, for example, by Sharif et al, (BMC Biochemistry (2012), 13:12), it is easy to assess through gel filtration experiments whether the reducing agent was effective and whether hTK-1 is present mainly as a tetramer after treatment. For the skilled artisan, several different reducing reagents are at stake, for example dithiothreitol (DTT), dithioerythritol (DTE), or dithiobutylamine (DTBA). In addition, the concentration of the pretreatment reagent is selected so that it does not negatively affect the antibody used to measure the hTK-1 protein, either after an appropriate incubation time or after a dilution step. When dithiobutylamine (DTBA) is used as a reducing agent, the appropriate final concentration of the sample pretreatment step (mixture of sample and pretreatment reagent) is in the range of 5 mM. By pre-dilution and / or addition of an agent that blocks DTT and / or dilution with the buffer containing the primary antibody, the concentration of the oxidized form of DTT is preferably 1.5 mM or less. In this way, there is no effect of the reducing agent on any of the immunological reagents used.

[0103] As explained above, ATP stabilizes the tetrameric form of hTK-1. The latter function of ATP makes it an attractive auxiliary for example to a pretreatment buffer. In one embodiment, the pretreatment buffer comprises a reducing agent as discussed above and ATP. The concentration of ATP in the sample pretreatment step should not be below 1.25 mM. An appropriate choice for the ATP concentration in the pretreatment step would be in the range of 2 mM to 20 mM.

[0104] As can be seen from the examples given, the value of the level of TK-1 is very useful for determining the prognostic indicator for DLBCL patients.In one embodiment, the present disclosure relates to the use of the value of the level of TK-1 in determining the prognostic indicator for DLBCL patients.

[0105] In one embodiment, the present disclosure relates to a prognostic index (PI) for DLBCL comprising a value for the level of thymidine kinase 1 combined with standard parameters (components) of any of the three PIs detailed above.

[0106] In one embodiment, the present invention relates to the use of the value of the level of TK-1 in combination with other standard parameters of prognostic index for DLBCL patients when determining said prognostic index.In one embodiment, the present disclosure relates to the use of TK-1 in determining prognostic index for DLBCL patients, and the value of the level of TK-1 is combined with other parameters used in IPI, age-adjusted IPI, R-IPI or NCCN-IPI.In one embodiment, the present disclosure relates to the use of TK-1 in determining prognostic index for DLBCL patients, and the value of the level of TK-1 is combined with other parameters used in R-IPI or NCCN-IPI.

[0107] In one embodiment, a value for the level of TK-1 is used, provided that the value for the level of TK-1 is used to replace the value for the level of LDH in such PI.

[0108] For any patient, especially for those who have recently been diagnosed with DLBCL, TK-1 can be measured and compared to a predefined cutoff value.If the measurement value for a newly diagnosed patient is above the predefined cutoff value, the patient will be considered to have a higher risk score and to be more likely to experience unfavorable disease outcomes.

[0109] In one embodiment, the present disclosure relates to a prognostic index (PI) for DLBCL that comprises a value for the level of thymidine kinase 1.

[0110] In one embodiment, the present disclosure relates to a prognostic index (PI) for DLBCL comprising a value for the level of thymidine kinase 1, wherein the PI is selected from IPI, age-adjusted IPI, R-IPI, or NCCN-IPI. In one embodiment, the present disclosure relates to a prognostic index (PI) for DLBCL comprising a value for the level of thymidine kinase 1, wherein the PI is selected from R-IPI, or NCCN-IPI.

[0111] These and other embodiments are disclosed and encompassed by the present specification and examples.Further literature on any one of the methods, uses and compounds to be employed according to the present invention can be retrieved from public libraries and databases, for example, by using electronic devices.For example, the public database "Medline" available on the Internet can be used, for example, on the World Wide Web at ncbi.nlm.nih.gov / PubMed / medline.html.Further databases and addresses available on the World Wide Web, such as ncbi.nlm.nih.gov / , fini.ch / biology / research_tools.html, tigr.org / , are known to those skilled in the art and can also be obtained using the address on the World Wide Web under lycos.com.

[0112] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the patent specification, including definitions, shall control.

[0113] All amino acid sequences provided herein begin with the most N-terminal residue and end with the most C-terminal residue (N→C), as is conventional in the art, and the one-letter or three-letter code abbreviations used to identify amino acids throughout the present invention correspond to those commonly used for amino acids.

[0114] The following embodiments are contemplated, as well as others described herein: The invention is not intended to be limited by the list of embodiments, and any embodiment that is properly supported by any portion of this specification may be claimed in this application or in any subsequent prosecution or continuation / division thereof.

[0115] 1. A first embodiment of a method for determining a prognostic index (PI) (also called risk score or PI score) for a patient with diffuse large B-cell lymphoma (DLBCL), the method comprising: a) At least the following parameters: i) extranodal disease status, ii) Ann Arbor stage, and iii) thymidine kinase 1 levels. determining The absence of extranodal disease was assigned a score of 0, the presence of extranodal disease was assigned a score of 1, Ann Arbor stage I or II is assigned a value of 0, Ann Arbor stage III or IV is assigned a value of 1, and determining a thymidine kinase level below the cutoff as a value of 0 and a thymidine kinase level above the cutoff as a value of at least 1; b) In determining the PI, add up the values ​​for i), ii), and iii) The present invention relates to a method comprising the steps of:

[0116] 2. The method of embodiment 1, wherein the thymidine kinase cutoff level is set at 4 times the average TK-1 level as determined in healthy individuals, with any thymidine kinase level below the cutoff being assigned a value of 0 and any TK-1 level above the cutoff being assigned a value of 1.

[0117] 3. The method of embodiment 1, wherein the thymidine kinase cut-off level is set at 4 times the average value of the TK-1 level as determined in healthy individuals, with low thymidine kinase levels, i.e. levels of TK-1 below the cut-off, being assigned a value of 0, intermediate thymidine kinase levels, i.e. levels of TK-1 above the cut-off and below a value corresponding to 20 times the average value as determined in healthy individuals, being assigned a value of 1, and high thymidine kinase levels, i.e. levels of TK-1 above 20 times the average value as determined in healthy individuals, being assigned a value of 2.

[0118] 4. The method of embodiment 1, wherein the protein level cutoff for TK-1 is equivalent to and includes 18 U / l of TK-1 enzyme activity.

[0119] 5. The method of embodiment 1, wherein the protein level cutoff is equal to and includes 18 U / l, and wherein a TK-1 level above 18 U / l and below 88 U / l is a value of 1 point, and a TK-1 level above 88 U / l is a value of 2 points.

[0120] 6. The method of any one of the preceding claims, further comprising a parameter of age, wherein in determining PI, if age is below the cutoff value, the value is 0 points, and if age is above the cutoff value, the value is 1 point.

[0121] 7. The method according to embodiment 6, wherein in the determination of PI, if the age is less than or equal to 60, the value is 0 points, and if the age is more than 60, the value is 1 point.

[0122] 8. The method according to any one of embodiments 1 to 5, further comprising a parameter called ECOG performance status, wherein in determining the PI, if the ECOG performance status is ≦1, the value is 0 points, and if the ECOG performance status is ≧2, the value is 1 point.

[0123] 9. The method according to any one of embodiments 1 to 5, further comprising a parameter of age and a parameter of ECOG performance status, wherein in determining PI, if the age is 60 or less, the value is 0 points, if the age is more than 60, the value is 1 point, and in determining PI, if the ECOG performance status is 1 or less, the value is 0 points, and if the ECOG performance status is 2 or more, the value is 1 point.

[0124] 10. The method according to any one of embodiments 1 to 5, further comprising a parameter of age and a parameter of ECOG performance status, wherein in determining PI, if the age is 40 or less, the value is 0 points, if the age is more than 40 and less than or equal to 60, the value is 1 point, if the age is more than 60 and less than or equal to 75, the value is 2 points, if the age is more than 75, the value is 3 points, and in determining PI, if the ECOG performance status is 1 or less, the value is 0 points, and if the ECOG performance status is 2 or more, the value is 1 point.

[0125] 11. An embodiment, which is the use of the value for the level of TK-1 in determining a prognostic indicator for DLBCL patients.

[0126] 12. The use according to embodiment 11, wherein the value for the level of TK-1 is combined with other parameters such as those used in the IPI, age-adjusted IPI, R-IPI, or NCCN-IPI.

[0127] 13. The use according to embodiment 11 or 12, provided that the value for the level of TK-1 is used to replace the value for the level of LDH in such PI.

[0128] 14. An embodiment, wherein the prognostic indicator (PI) for DLBCL comprises a value for the level of thymidine kinase 1.

[0129] 15. The prognostic index (PI) of embodiment 14, wherein the PI is selected from an IPI, an age-adjusted IPI, an R-IPI, or an NCCN-IPI.

[0130] With respect to the embodiments characterized in this specification, and in particular in the claims, it is intended that each embodiment mentioned in a dependent claim be combined with each embodiment of each claim (independent or dependent) on which the dependent claim depends. For example, in the case of independent claim 1 reciting three alternatives A, B and C, dependent claim 2 reciting three alternatives D, E and F, and claim 3 which is dependent on claims 1 and 2 and reciting three alternatives G, H and I, it will be understood that the specification expressly discloses embodiments corresponding to combinations A,D,G;A,D,H;A,D,I;A,E,G;A,E,H;A,E,I;A,F,G;A,F,H;A,F,I;B,D,G;B,D,H;B,D,I;B,E,G;B,E,H;B,E,I;B,F,G;B,F,H;B,F,I;C,D,G;C,D,H;C,D,I;C,E,G;C,E,H;C,E,I;C,F,G;C,F,H;C,F,I.

[0131] Similarly, it is understood that if an independent claim and / or a dependent claim does not recite alternatives, then if a dependent claim refers to more than one preceding claim, any combination of the subject matter covered thereby is considered to be explicitly disclosed. For example, in the case of independent claim 1, dependent claim 2 referring to claim 1, and dependent claim 3 referring to both claims 2 and 1, it follows that the combination of the subject matter of claims 3 and 1 is clearly and unambiguously disclosed, as is the combination of the subject matter of claims 3, 2 and 1. If there is a further dependent claim 4 referring to any one of claims 1 to 3, it follows that the combination of the subject matter of claims 4 and 1, claims 4, 2 and 1, claims 4, 3 and 1, and claims 4, 3, 2 and 1 are clearly and unambiguously disclosed.

[0132] The above considerations apply mutatis mutandis to all of the appended claims. To provide a non-limiting example, the combination of claims 8, 5, and 1 is clearly and unambiguously envisaged in terms of claim structure. The same applies to combinations such as, for example, claims 8, 7, and 2. EXAMPLES

[0133] (Example) The following examples illustrate the invention.

[0134] Example 1: Materials and General Methods Protein Chemistry and Labeling Technologies Standard protein chemistry and labeling techniques are provided, for example, in Hermanson, G. "Bioconjugate Techniques" 3rd Edition (2013) Academic Press.

[0135] bioinformatics Bioinformatics methods are provided, for example, in Keith JM (ed.) “Bioinformatics” Vol. I and Vol. II, Methods in Molecular Biology Vol. 1525 and Vol. 1526 (2017) Springer, and in Martin, ACR & Allen, J. “Bioinformatics Tools for Analysis of Antibodies” in: Dubel S. & Reichert JM (eds.) “Elandbook of Therapeutic Antibodies” Wiley-VCH (2014).

[0136] Electrochemiluminescence immunoassay Immunoassays and related methods are provided, for example, in Wild D. (ed.) "The Immunoassay Handbook" 4th Edition (2013) Elsevier. Ruthenium complexes as electrochemiluminescent labels are provided, for example, in Staffilani M. et al. Inorg. Chem. 42 (2003) 7789-7798. Typically, for the performance of electrochemiluminescence (ECL)-based immunoassays, an Elecsys 2010 analyzer or successor system is used, for example, Roche analyzers such as E170, Corbus e601 module, Corbus e602 module, Corbus e801 module and Corbus e411 (Roche Diagnostics GmbH, Mannheim Germany), and the Roche Elecsys assays designated for these analyzers, each used under standard conditions unless otherwise stated.

[0137] Example 2: Anti-hTK-1 antibody hTK-1, clone 6C6, heavy chain: (SEQ ID NO:3) METGLRWLLLVAVLKGVQCQEQLEESGGDLVKPEGSLTLTCTASRFSFSSSYWICWVRQAPGKGLEWIACIYAGDSGSSYYASWAKGRFTVSKTSSTTVTLQTTSLTAADTATYFCARASVGAAYDYFALWGPGTLVTVSSGQPKAPSVFPLAPCCGDTPSSTVTLGCLVKGYLPEPVTVTWNSG

[0138] hTK-1, clone 6C6, light chain: (SEQ ID NO: 4) MDTRAPTQLLGLLLLWLPGARCALVMTQTPASVEAAMGGTVTIKCQASEDVSSHLAWYQQRPGQPPKLLIYGASDLASGVPSRFTGSGSGTQFTLAISDLECADAATYYCQGYYYISD SPYVFGGGTEVVVKGDPVAPTVLIFPPAADQVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTGIENSKTPQNSADCTYNLSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFNRGDC

[0139] hTK-1, clone 4H4, heavy chain: (SEQ ID NO: 7) METGLRWLLLVAVLKGVQCQSLEESGGGLVQPEGSLTLTCTASGFSFSSGYDMCWVRQTPGKGLEWIACISVDSDGVTYYASWAKGRFTISKTSSTTVTLQMTSLTAADTATYFCARGYESSSGVYIPYFTLWGPGTLVTVSSGQPKAPSVFPLAPCCGDTTPSSTVTLGCLVKGYLPEP VTVTWN SG

[0140] hTK-1, clone 4H4, light chain: (SEQ ID NO:8) MDMRAPTQLLGLLLLWLPGARCADIVLTQTPASVEAAVGGTVTIKCQASQSIYSYLAWYQHKPGQPPKLLIYKASTLASGVPSRFKGSGSGTEYTLTISDLECADAATYYCQHYYYSST SGGGVFGGGTEVVVKGDPVAPTVLIFPPAADQVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTGIENSKTPQNSADCTYNLSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFNRGDC

[0141] hTK-1, clone 23C11, heavy chain: (SEQ ID NO:9). METGLRWLLLVAVLKGVQCQSLEESGGRLVTPGTPLTLTCTASGFSLSNYYMSWVRQAPGKGLEWIGIIYGDDNTYCANWTKGRFTISKTSTTVDLTITSPTTSTEDTATYFCARGPDYIAAKMDIWGPGTLVTVSLGQPKAPSVFPLAPCCGDTPSSSTVTLGCLVKGYLPEP VTVTWNSG

[0142] hTK-1, clone 23C11, light chain: (SEQ ID NO: 10) MDTRAPTQLLGLLLLWLPGARCDVVMTQTPASVEAAVGGTVTIKCQASQSISGYLSWYQQKPGQRPKLLIYRASTLESGVPSRFKGSGSGTEFTLTISDLECADAATYYCQCTYGSSTF SSYGNAFGGGTEVVVKGDPVAPTVLIFPPAADQVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTGIENSKTPQNSADCTYNLSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFNRGDC

[0143] As is apparent, the full length immunoglobulin or any binding fragment thereof (if desired / required) can be readily determined by one of skill in the art based on the sequences disclosed above.

[0144] Example 3: Epitope Characterization As described in Example 2, four different monoclonal antibodies could be generated that exhibit the necessary binding characteristics needed to be useful in the development of immunoassays.

[0145] In a first attempt to characterize the epitopes bound by the newly generated antibodies, a PepScan analysis was performed. For this analysis, synthetic peptides, each consisting of 15 amino acids, were synthesized, each shifting by one amino acid (1-15, 2-16, etc.) and spanning the entire sequence of hTK-1 (SEQ ID NO:1). These PepScan peptides were spotted onto microscope slides. After blocking for nonspecific binding, cell culture supernatants of the various MABs were incubated on the microscope slides. Unbound MABs were washed away by standard methods, and bound MABs were detected by the use of HRP-conjugated goat anti-rabbit IgG.

[0146] Only one of the four MABs (antibody 4H11) obtained by the method of Example 2 reacted with a linear epitope. As can be seen, the epitope bound by this antibody is contained in the sequence spanning amino acid residues 211 to 230 of hTK-1 (SEQ ID NO:6).

[0147] Polyclonal and monoclonal antibodies reacting with synthetic peptides corresponding to the polypeptide consisting of amino acids 194-225 of hTK-1 (SEQ ID NO:2) are known in the prior art, see for example WO2015 / 094106. Three MABs, namely 4H4, 6C6 and 2301, did not bind to the polypeptide consisting of amino acids 194-225 of hTK-1 (SEQ ID NO:2) and did not show significant binding to any of the PepScan peptides tested. This indicates that all three MABs bind to conformation-dependent epitopes of hTK-1. Since these three MABs appeared very promising from the outset for further assay development, additional efforts were made to deepen knowledge of the epitopes to which these three MABs bind.

[0148] Epitope characterization by competition experiments was performed on a GE Healthcare Biacore 4000 at 25°C. A Biacore Biotin Capture Kit, Series S Sensor (Cat. No. 28-9202-34) was installed in the instrument, hydrodynamically addressed and preconditioned according to the manufacturer's instructions. The system buffer was HBS-N (10 mM HEPES pH 7.4, 150 mM NaCl). The sample buffer was system buffer. Biotin capture reagent provided by manufacturer GE Healthcare was diluted 1:50 in system buffer and injected at 10 μl / min for 60 seconds on flow cells 1, 2, 3 and 4 to process spots 1, 2 and 4, 5. Spot 3 served as a reference. 10 nM biotinylated primary antibody was injected at 30 μl / min for 120 seconds contact time to process spots 1 and 5 on all four flow cells. Spots 2 and 4 served as controls. 10 nM human recombinant thymidine kinase 1 (hTK-1, Roche, 114 kDa, tetramer) was injected at 30 μl / min for a contact time of 180 s into all flow cells to treat spots 1, 2 and 4, 5. To block remaining accessible epitopes of the primary antibody, 100 nM of non-biotinylated primary antibody was injected again at 30 μl / min to treat spots 1, 2 and 4, 5 of all flow cells for 180 s. 100 nM of secondary antibody was injected at 30 μl / min for a contact time of 180 s into all flow cells to treat spots 1, 2 and 4, 5. Finally, the complexes formed on the sensor surface were completely removed by a regeneration step with a contact time of 120 s in all flow cells and all spots using the regeneration solution provided by the manufacturer, GE Healthcare.

[0149] In this manner, the accessibility characteristics of the hTK-1 epitope were investigated for four recombinant monoclonal rabbit IgG antibodies: antibody 4H11 (an antibody that binds to an epitope contained within amino acids 211-230 (SEQ ID NO: 6) of hTK-1 and rabbit MABs 23C11, 6C6 and 4H4);

[0150] Reporting points were set before and after each sample injection. Readout of reporting points in response units (RU) was performed by using Biacore Evaluation version 1.1 software.

[0151] To the first biotinylated primary antibody capture signal (bi-Ab1, [RU]), a second binding response signal of a non-biotinylated primary antibody (block Ab1 [RU]) was added. Molar ratio epitope accessibility MR EA = Ab2 [RU] / (bi-Ab1 [RU] + block Ab1 [RU]) was calculated and used as an estimate for epitope accessibility for each antibody used in the assay.

[0152] To verify the tetrameric state of the hTK analyte, a second molar ratio was calculated from the hTK binding signal relative to the capture level of the biotinylated primary antibody by using the formula MR = hTK [RU] / bi-Ab1 [RU] × molecular weight bi-Ab1 (150 kDa) / molecular weight hTK (114 kDa).

[0153] For example, antibody 4H11 showed a 1:1 binding stoichiometry (= molar ratio) antibody 4H11 / hTK-1 MR. In this biosensor assay, a single tetrameric hTK-1 molecule is bound to a single antibody 4H11 molecule. Of the described antibodies, only antibody 4H11 shows homologous hTK-1 complex formation when used as a blocking Ab. Therefore, a sandwich assay would be possible by using a sequential assay protocol using antibody 4H11 twice. For rabbit monoclonal antibodies MAB 23C11, 6C6, and 4H4, no homologous complex formation could be detected. This means that MAB 23C11, 6C6, and 4H4 bind to the same epitope region. Antibodies 23C11, 6C6, and 4H4 form a sandwich with antibody 4H11 as the secondary antibody. According to this assay, the best performing sandwich pair was 6C6 as the biotinylated primary antibody, complexed with antibody 4H11, at a molar ratio of MR EA= 0.4, which means an epitope accessibility of 40% in the hTK assay.

[0154] As can be seen from the table below, antibody 4H11 (which binds to a C-terminal linear epitope contained in SEQ ID NO:6) can form immune complexes with 23C11, 6C6 and 4H4, while it is clear that rabbit monoclonal antibodies MAB 23C11, 6C6 and 4H4 share the same epitope (see Table 3 below). [Table 3]

[0155] Sandwich formation of four anti-hTK-1 antibodies using recombinant h-TK-1 as analyte in solution is shown. A value of 0.0 in the table indicates that the primary and secondary antibodies used bind to the same epitope. A value of 0.1 or higher indicates sandwich formation despite an intermediate blocking step, i.e. the two antibodies studied bind to different epitopes.

[0156] Example 4: Generation of MAB conjugates for use in Elecsys immunoassay experiments The procedures used are familiar to those skilled in the art, therefore it is considered redundant to give experimental details.

[0157] Briefly, the following procedure / steps were performed to obtain antibody conjugates for the capture and detection sides of the immunological assay.

[0158] Cell culture supernatant (containing recombinant antibodies) obtained from cells generated by B cell PCR (see above) was used as starting material.

[0159] The recombinant antibodies contained in the tissue culture supernatants were purified by affinity chromatography against Protein A.

[0160] The antibody used as the capture antibody was cleaved into F(ab')2 fragments with pepsin, and the F(ab')2 fragments were further purified by affinity and size-exclusion chromatography. The F(ab')2 fragments were then reduced to Fab' and site-specifically biotinylated via thiol chemistry to obtain monobiotinylated Fab' fragments.

[0161] The antibody used as the detection antibody was prepared by the procedure described in the art as sulfo-BPRu NHS ester (=ruthenate(2-),bis[[2,2'-bipyridine]-4,4'-dimethanesulfonato(2-)-κN 1 ,κN 1 ][1-[4-(4'-methyl[2,2'-bipyridin]-4-yl-κN 1 ,κN 1 The label was chemically coupled to sulfo-ruthenium (WO 2003 / 002974) using CAS Registry Number 482618-42-8), also known as [[(OC-6-31)]-1-oxobutoxy]-2,5-pyrrolidinedione]-, sodium (1:2), (OC-6-31), and unbound label was removed by size exclusion chromatography.

[0162] Example 5: Samples and hTK-1 measurements 5.1 Sample A "black and white" panel was investigated: on the one hand, serum samples from 50 (for some experiments only 49 were still available) healthy donors were used for the quantification of hTK-1 in various assays; on the other hand, hTK-1 was measured in 48 samples (for some experiments only 47 were still available) from patients with diffuse large B-cell lymphoma (DLBCL).

[0163] 5.2 Prototype electrochemiluminescence immunoassay Based on the monoclonal rabbit antibodies obtained as described in Example 3, purified and conjugated as described in Example 4, several prototype immunoassays have been established.

[0164] A typical setup for a prototypic electrochemiluminescence immunoassay uses a biotinylated capture antibody (or antigen-binding fragment thereof) and a detection antibody (or antigen-binding fragment thereof) labeled with a ruthenium complex.

[0165] In most cases, the immunoassay data were generated by conventional procedures using biotinylated conventional Fab' fragments. The measurements were carried out in a sandwich assay format on a cobas® E170 analyzer from Roche. Signal detection in the cobas® E170 analyzer is based on electrochemiluminescence. In this sandwich assay, a biotin conjugate (i.e., a capture antibody) is immobilized on the surface of streptavidin-coated magnetic beads. The detection antibody has a complexed ruthenium cation as a signaling moiety. In the presence of the analyte, a chromogenic ruthenium complex is crosslinked to the solid phase and emits light at 620 nm after excitation at a platinum electrode contained in the measuring cell of the cobas® E170 analyzer. The signal output is in arbitrary light units.

[0166] Measurements were performed using calibrators spiked with, for example, recombinant hTK-1 from HEK cells, and human serum samples as previously described.

[0167] The experimental hTK-1 assay was performed as follows: 25 μl of human serum sample or spiked calibrator, 25 μl of pretreatment reagent (containing 10 mM DTBA) were mixed and incubated for 9 minutes, after which 60 μl of capture antibody-biotin complex and 60 μl of detection antibody ruthenium-labeled complex were incubated together for another 9 minutes, followed by the addition of 30 μl of streptavidin-coated paramagnetic microparticles. The final mixture was incubated for another 9 minutes. hTK-1 was then detected as usual (i.e., via the electrochemiluminescence signal generated in these experiments).

[0168] Below are given the results obtained for the combination of biotinylated 6C6 (used as Fab'-Bi) and ruthenylated 4H11 (used as IgG).

[0169] The calibration results are given in Table 4 below. [Table 4]

[0170] Table 4 gives the signals obtained in the prototype immunoassay using various amounts of recombinant hTK-1 as analyte. Duplicate measurements were performed.

[0171] Box plots were calculated, receiver operator characteristics (ROC) were analyzed, and the area under the curve (AUC) was determined. For the prototype immunoassay, the AUC was 0.965. Both the determined box plots and AUC of the concentrations of hTK-1 are shown in FIG. 1.

[0172] 5.3 DiaSorinTK-1 activity assay The LIAISON® Thymidine Kinase Assay, manufactured by DiaSorin, is an indirect modified two-step competitive chemiluminescence immunoassay (CLIA) for the quantitative measurement of TK in human serum and EDTA plasma. The LIAISON® Thymidine Kinase Assay was performed according to the instructions given by the manufacturer using 50 control samples and 48 samples from DLBCL patients. It utilizes an initial enzymatic reaction in which TK in the sample converts AZT (3'-azido-3'-deoxythymidine) to AZTMP (3'-azido-3'-deoxythymidine monophosphate), followed by a competitive immunoassay for the quantitative measurement of AZTMP. The amount of AZT converted to AZTMP is a measure of the amount of TK present in the sample. In the assay, 50 μL of sample was incubated with 100 μL of Assay Buffer 1, 20 μL of Assay Buffer 2, and 20 μL of paramagnetic particles coated with anti-AZTMP polyclonal antibody. Rabbit anti-goat IgG, then anti-AZTMP goat polyclonal are coated onto the solid phase. This is incubated for 40 minutes, after which 100 μL of tracer (AZTMP analogue bound to an isoluminol derivative) is added. During the first incubation, AZTMP binds to the solid phase. In the second incubation, the tracer complex competes for binding with AZTMP in solution. After a 20-minute incubation, unbound material is removed with a wash cycle. The starting reagent is then added, initiating the flash chemiluminescence reaction. The light signal is measured by a photomultiplier tube as relative light units (RLU) and is proportional to the concentration of TK present in the calibrator, control, or sample.

[0173] Box plots were calculated, receiver operator characteristics (ROC) were analyzed, and the area under the curve (AUC) was determined. For the LIAISON® thymidine kinase assay, the AUC was found to be 0.958. Both the box plots and the AUC are shown in FIG. 2.

[0174] Example 6: Comparison of TK-1 values ​​measured using activity assays / immunoassays The values ​​obtained with the LIAISON® thymidine kinase assay, on the one hand, and with a prototype immunoassay, on the other hand, were compared with each other. Taking into account that one assay measures thymidine kinase activity, whereas the other assay measures the amount of immunoreactive hTK-1, a surprisingly high correlation (in the range of 0.95 or higher - depending on the statistical method used) was found between the two different assays. The good correlation between these different assays for hTK-1 is also very evident from Figure 3.

[0175] Example 7: Use of TK-1 values ​​as a key component of prognostic indicators 7.1 Analytical approach The prognostic power of thymidine kinase 1 (TK-1) was retrospectively evaluated using samples from the pharmacological MAIN trial conducted in patients with diffuse large B-cell lymphoma (DLBCL) [Seymour et al., 2014], where serum TK-1 concentrations were measured in each of the 407 baseline samples still available, using an assay called prototype B in Example 5.2. Progression-free survival (PFS) event rates within this subset were very similar to the PFS of the full study population (both approximately 31%).

[0176] To make a fair comparison of all multivariate models, we created a data subset to include only samples with all relevant data points (TK-1 measurements and all index components). This resulted in a final analysis dataset containing 370 samples, of which 116 were from patients who experienced a PFS event within 3 years after the start of R-CHOP treatment. Due to the small number of samples with event-free follow-up of more than 3 years, samples were censored at the 3-year point.

[0177] To assess whether the prognostic value of TK-1 was independent of known clinical and demographic risk factors, Cox proportional hazards models for each of the three described prognostic indices, including the risk components of each index and the log2-transformed TK-1 value, were calculated.

[0178] 7.2 Contribution of TK-1 to R-IPI and NCCN-IPI To evaluate the ability of TK-1 to improve existing risk scores for PFS prognosis, we either extended the index components with log2-transformed TK-1 values ​​or replaced the FDH component with log2 TK-1 values. Both extensions and replacements were performed by creating Cox partitioned hazard models that included each risk component as an independent variable and comparing the c-indexes of the original models (R-IPI and NCCN-IPI) with the c-indexes of the TK-1-extended models (with and without the LDH component, respectively). The significance of the p-values ​​of each difference was assessed with a bootstrap resampling approach.

[0179] a) TK-1 as a covariate for R-IPI The results of the statistical analysis of the contribution provided by TK-1 to the R-IPI are given in Table 5 below. [Table 5]

[0180] A Cox proportional hazards model combining the binary R-IPI risk components with TK-1 (log2 transformed) clearly shows that TK-1 adds substantial prognostic information to the model. The hazard ratio (HR) is approximately 1.3, with the minimum p-value for all model components being <0.001 (see Table 5). The hazard ratio can be interpreted as a two-fold increase in TK-1 being associated with a 1.3-fold increase in risk for a PFS event (i.e., disease progression or death).

[0181] For the trichotomized TK-1 scenario, TK-1 concentrations were first stratified into three groups (i.e., low, intermediate, and high levels). The optimal cutoff value was determined in a univariate setting by maximizing the log-rank statistic (i.e., maximizing the difference between the three survival curves in the Kaplan-Meier analysis) while ensuring that there were at least 10 samples in each group. This determined the following ranges: [Table 6]

[0182] Based on method comparisons between measurements of Roche Elecsys TK-1 concentration and Diasorin TK-1 activity, these ranges can be further expressed in terms of U / L, based on the correlation of 1 ng / ml of TK-1 (Roche) to approximately 25 U / L of TK-1 (Diasorin). The average activity in healthy individuals was reported to be 4.3 U / L with Diasorin used as a relative reference for the cutoff value. [Table 7]

[0183] In the multivariate Cox model, the trichotomized TK-1 values ​​contribute significantly to the prognostic power with p-values ​​of 0.013 and <0.001 for intermediate vs. low and high vs. low TK-1 levels, respectively (see Table 6). The corresponding hazard ratios are 2.11 and 5.40, meaning that patients with intermediate TK-1 levels have approximately 2.1-fold higher risk of a PFS event than patients with low TK-1, and even 5.4-fold higher risk for patients with high TK-1 levels. [Table 8]

[0184] b) TK-1 as a covariate in the NCCN-IPI The results of the statistical analysis of the contribution provided by TK-1 to the NCCN-IPI are given in Table 7 below. [Table 9]

[0185] A multivariate model combining the dichotomized NCCN-IPI risk components with TK-1 (log2 transformed) also shows a significant additional prognostic value of TK-1 (p-value=0.009, see Table 7). The hazard ratio (HR) is approximately 1.25, only slightly smaller than the R-IPI model.

[0186] The results of the statistical analysis of the contributions provided to the NCCN-IPI by the trichotomized TK-1 are presented in Table 8 below. [Table 10]

[0187] A model combining the dichotomized NCCN-IPI risk components with TK-1 (trichotomous) shows a significant additional prognostic value of TK-1 (intermediate vs. low: p-value = 0.011, high vs. low: p-value < 0.001, see Table 8). The corresponding HRs are 2.15 and 4.72, respectively, and are also very similar to their R-IPI counterparts.

[0188] 7.3 TK-1 improves the prognostic ability of R-IPI and NCCN-IPI A widely used measure of the prognostic ability of hazard models is the c-index, which can be considered as the area under the ROC curve analogue (AUC) in survival models. Table 9 shows the calculated c-indexes for the investigated prognostic indices (R-IPI and NCCN-IPI) and the c-indexes for the TK-1 extended model with and without the respective dichotomized LDH component. The inclusion of TK-1 improves these indices by 3.2%-4%, regardless of the presence of LDH (see also Table 9). Although this improvement can be considered clinically relevant and is also statistically significant in most cases, we could not show a significant improvement of the c-index (i.e., the confidence intervals of the bootstrap system do not include 0, except for NCCN-IPI vs. NCCN-IPI+TK-1 (log2) without LDH and KPI vs. KPI+TK-1 (log2) without LDH (see Table 10)). This clearly indicates that TK-1 not only improves the prognostic indicators investigated but may even replace LDH in these indicators. [Table 11] [Table 12]

[0189] The data presented in Tables 9 and 10, respectively, clearly show that TK-1 can be used in combination with existing prognostic indicators to significantly improve clinical scores in predicting disease outcomes for DLBCL patients. The inclusion of TK-1 improved each of the prognostic indicators examined.

[0190] As is evident from Tables 9 and 10, TK-1 may even replace LDH within these indices, since in the case of two prognostic indexes (R-IPI and KPI), the c-values ​​become slightly better if LDH is omitted, whereas in the case of NCCN-IPI, they become only slightly worse if LDH is not included.

[0191] For new patients diagnosed with DLBCL, TK-1 should be measured and compared to a predefined cutoff value, especially before treatment is started. If the measurement for the new patient is above the predefined cutoff value, the patient will be considered to have a higher risk score and be more likely to experience an unfavorable disease outcome.

Claims

1. 1. A method for determining a prognostic index (PI) (also called risk score or PI score) for a diffuse large B-cell lymphoma (DLBCL) patient, comprising: a) at least the following parameters: i) extranodal disease status, ii) Ann Arbor stage, iii) thymidine kinase 1 (TK-1) level, iv) age, and v) ECOG (Eastern Cooperative Oncology Group) performance status. determining The absence of extranodal disease was assigned a score of 0, the presence of extranodal disease was assigned a score of 1, Ann Arbor stage I or II was assigned a value of 0, and Ann Arbor stage III or IV was assigned a value of 1; determining that a level of TK-1 equal to or below a cutoff is assigned a value of 0 and that a level of TK-1 above said cutoff is assigned a value of at least 1; If the age is below the cutoff, the value is 0 points, and if the age is above the cutoff, the value is 1 point; and If the ECOG performance status is 1 or less, the score is 0; if the ECOG performance status is 2 or more, the score is 1. b) summing the values ​​for i), ii), and iii) in said determining said PI; The method includes:

2. 2. The method of claim 1, wherein the TK-1 cut-off level is set at 4 times the average TK-1 level as determined in healthy individuals, a TK-1 level below the cut-off being assigned a value of 0 and any TK-1 level above the cut-off being assigned a value of 1.

3. 2. The method of claim 1, wherein the TK-1 cut-off level is set at 4 times the average value of TK-1 levels as determined in healthy individuals, low TK-1 levels, i.e. levels of TK-1 below said cut-off, are assigned a value of 0, intermediate TK-1 levels, i.e. levels of TK-1 above said cut-off and below a value corresponding to 20 times the average value as determined in healthy individuals, are assigned a value of 1, and high TK-1 levels, i.e. levels of TK-1 above 20 times the average value as determined in healthy individuals, are assigned a value of 2.

4. 2. The method of claim 1, wherein the protein level cutoff for TK-1 is equivalent to and includes 18 U / l of TK-1 enzyme activity.

5. The method of claim 1, wherein the level of TK-1 is a protein level of TK-1.

6. 6. The method of claim 5, wherein said cut-off of said protein level is equal to and includes 18 U / l, and wherein a TK-1 level above 18 U / l and below 88 U / l is assigned a value of 1 point, and a TK-1 level above 88 U / l is assigned a value of 2 point.

7. 2. The method of claim 1, wherein in said determining said PI, if said age is 60 or less, said value is 0 points and if said age is greater than 60, said value is 1 point.

8. 7. The method according to any one of claims 1 to 6, further comprising the parameters of age and ECOG performance status, wherein in said determination of said PI, if said age is less than or equal to 40, said value is 0 points, if said age is greater than 40 and less than or equal to 60, said value is 1 point, if said age is greater than 60 and less than or equal to 75, said value is 2 points, and if said age is greater than 75, said value is 3 points.

9. 1. Use of values ​​for i) extranodal disease status, ii) Ann Arbor stage, iii) thymidine kinase 1 (TK-1) level, iv) age, and v) ECOG (Eastern Cooperative Oncology Group) performance status in determining a prognostic index for DLBCL patients, wherein a prognostic index above a cutoff indicates an increased risk of unfavorable disease outcome.

10. 10. The use according to claim 9, wherein the values ​​of i) to v) are combined with other parameters such as those used in the IPI, age-adjusted IPI, R-IPI, or NCCN-IPI.

11. The use according to claim 9 or 10, provided that said value for said level of TK-1 is used to replace the value for the level of LDH in such PI.

12. 1. A computer readable program product comprising instructions that, when executed by a computer, cause a computer to determine a prognostic index (PI) for DLBCL comprising values ​​for i) extranodal disease status, ii) Ann Arbor stage, iii) thymidine kinase 1 (TK-1) level, iv) age, and v) ECOG (Eastern Cooperative Oncology Group) performance status.

13. The computer readable program product of claim 12 , wherein the program is implemented within an app.

14. A computer readable program product according to claim 12 or 13, wherein the PI is calculated as defined in any one of claims 1 to 8.

15. The computer readable program product of any one of claims 12 to 14, wherein the PI is selected from an IPI, an age-adjusted IPI, an R-IPI, or an NCCN-IPI.

Citation Information

Patent Citations

  • Methods of Prognosis for Non-Hodgkin Lymphoma

    US20120134986A1

  • Methods for Predicting the Survival Time of Patients Suffering from Diffuse Large B-Cell Lymphomas

    US20150377891A1